{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-028304","form_type":"8-K","ticker":"LNSR","cik":"0001320350","company_name":"LENSAR, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.357252+00:00","generated_at":"2026-06-24T02:38:50.396701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LENSAR Q2 revenue $8.0M (+1% YoY), net loss ($6.8M); FDA OK for ALLY system","bullets":["Net loss of ($6.8M) or ($0.67)/share vs. ($4.4M) or ($0.47)/share in Q2 2021.","Total procedure volume up 8% to 33,359; U.S. volume up 15% vs. Q2 2021.","Selling, general & administrative expenses rose 37% to $7.6M; R&D up 28% to $3.8M.","Adjusted EBITDA (ex stock comp) was ($4.3M) vs. ($2.3M) a year ago.","FDA cleared ALLY Adaptive Cataract Treatment System in June; expects ~10 U.S. placements in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-028304","json":"https://secwatch.observer/filing/0001564590-22-028304.json","markdown":"https://secwatch.observer/filing/0001564590-22-028304.md","text":"https://secwatch.observer/filing/0001564590-22-028304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000156459022028304/0001564590-22-028304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000156459022028304/lnsr-8k_20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:38:50.396701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}